Biotest AG: Expansion of product offering and capacity
Biotest AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Expansion of product offering and capacity
- Immunoglobulin Hepactect(R) CP approved for additional European countries
- Approval of a second immunoglobulin production plant
- Annual production capacity doubled to four tonnes
Dreieich, 7 April 2009. The Biotest Group has expanded the sales and
marketing base for its plasma proteins business and increased the
production capacity.
Hepatitis B immunglobulin Hepatect(R) CP has been approved for distribution
in seven additional European countries by the Mutual Recognition procedure
(MR).
The preparation is now also approved for use in Spain in the prevention of
Hepatitis B reinfection. Hepatect(R) CP is the first Hepatitis B
immunoglobulin to be approved in Spain for intravenous application in the
treatment of patients at every stage during and after liver
transplantation. The preparation has already been used there for some time
under the terms of special permission granted for use on compassionate
grounds. The official approval means that it can now be made accessible to
a larger group of patients.
With immediate effect, Biotest has doubled the previous production capacity
of immunglobulins, which now amounts to an availability of four tonnes. The
second production facility in Dreieich went on stream as soon as the
approval procedure was completed on 19 March 2009. Batches of the
polyvalent immunoglobulin Intratect(R) produced at the new plant are now
available for distribution in Europe. Work on an immunoglobulin production
facility with an annual capacity of around 1.5 tonnes based at the
headquarters of Biotest's US subsidiary, Biotest Pharmaceuticals Corp., are
also proceeding according to plan.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and leukaemia. The
products of the Microbiological Monitoring segment are primarily used in
hygiene monitoring, while those of Medical Diagnostics are used, for
example, in blood transfusions and transplants. Biotest has around 2,000
employees worldwide. The shares of Biotest AG are listed in the SDAX on the
Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit tel.: +49 (0) 6103 801-4406,
e-mail: monika_buttkereit@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
07.04.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
